Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience (NASDAQ: TWST) has announced the granting of 123,024 equity awards to 32 newly hired employees as employment inducements. The awards consist of 72,394 restricted stock units (RSUs) and up to 50,630 performance stock units (PSUs).
The RSUs will vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs will vest based on performance metrics set by the Board's Compensation Committee, achievable by the end of fiscal 2027 at 50%-140% of target. Both are subject to continued employment.
These awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4) for new hires or those returning after non-employment periods.
Twist Bioscience (NASDAQ: TWST) ha annunciato l'assegnazione di 123.024 premi azionari a 32 nuovi dipendenti come incentivo all'assunzione. I premi consistono in 72.394 unità azionarie vincolate (RSU) e fino a 50.630 unità azionarie legate alle performance (PSU).
Le RSU matureranno nel corso di 48 mesi, con il 25% che matura dopo un anno e 1/16 che matura trimestralmente successivamente. Le PSU matureranno in base a metriche di performance stabilite dal Comitato per la Retribuzione del Consiglio, raggiungibili entro la fine dell'esercizio fiscale 2027 tra il 50% e il 140% dell'obiettivo. Entrambi sono soggetti a un'occupazione continuativa.
Questi premi sono stati assegnati nell'ambito del Piano di Incentivazione Azionaria Modificato e Ripristinato di Twist, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) per nuovi assunti o per coloro che tornano dopo periodi di non occupazione.
Twist Bioscience (NASDAQ: TWST) ha anunciado la concesión de 123.024 premios de acciones a 32 nuevos empleados como incentivos de contratación. Los premios consisten en 72.394 unidades de acciones restringidas (RSUs) y hasta 50.630 unidades de acciones de rendimiento (PSUs).
Las RSUs se consolidarán durante 48 meses, con el 25% consolidándose después de un año y 1/16 consolidándose trimestralmente a partir de entonces. Las PSUs se consolidarán en función de las métricas de rendimiento establecidas por el Comité de Compensación de la Junta, alcanzables para finales del año fiscal 2027 entre el 50% y el 140% del objetivo. Ambos están sujetos a empleo continuo.
Estos premios fueron otorgados bajo el Plan de Incentivos de Capital Modificado y Restablecido de Twist, cumpliendo con la Regla de Cotización Nasdaq 5635(c)(4) para nuevas contrataciones o aquellos que regresan después de períodos de no empleo.
트위스트 바이오사이언스 (NASDAQ: TWST)는 32명의 신규 직원에게 123,024개의 주식 보상을 고용 유인으로 부여한다고 발표했습니다. 이 보상은 72,394개의 제한 주식 단위(RSU)와 최대 50,630개의 성과 주식 단위(PSU)로 구성됩니다.
RSU는 48개월 동안 분할 지급되며, 1년 후 25%가 지급되고 이후에는 분기마다 1/16이 지급됩니다. PSU는 이사회 보상위원회가 설정한 성과 기준에 따라 지급되며, 2027 회계연도 말까지 목표의 50%-140% 달성이 가능합니다. 두 가지 모두 지속적인 고용을 조건으로 합니다.
이 보상은 트위스트의 수정 및 재설정된 유인 주식 인센티브 계획에 따라 부여되었으며, 신규 채용 또는 비고용 기간 후 복귀하는 직원에 대한 NASDAQ 상장 규칙 5635(c)(4)를 준수합니다.
Twist Bioscience (NASDAQ: TWST) a annoncé l'octroi de 123.024 attributions d'actions à 32 nouveaux employés en tant qu'incitations à l'embauche. Les attributions se composent de 72.394 unités d'actions restreintes (RSU) et jusqu'à 50.630 unités d'actions de performance (PSU).
Les RSU seront acquises sur une période de 48 mois, avec 25% acquis après un an et 1/16 acquis trimestriellement par la suite. Les PSU seront acquis en fonction des critères de performance établis par le Comité de Rémunération du Conseil, atteignables d'ici la fin de l'exercice fiscal 2027 entre 50% et 140% de l'objectif. Les deux sont soumis à un emploi continu.
Ces attributions ont été accordées dans le cadre du Plan d'Incentive en Actions Modifié et Restitué de Twist, conformément à la Règle de Cotation Nasdaq 5635(c)(4) pour les nouvelles recrues ou celles revenant après des périodes de non-emploi.
Twist Bioscience (NASDAQ: TWST) hat die Vergabe von 123.024 Aktienoptionen an 32 neu eingestellte Mitarbeiter als Einstellungshilfen bekannt gegeben. Die Optionen bestehen aus 72.394 eingeschränkten Aktieneinheiten (RSUs) und bis zu 50.630 leistungsabhängigen Aktieneinheiten (PSUs).
Die RSUs werden über 48 Monate ausgezahlt, wobei 25% nach einem Jahr und 1/16 anschließend vierteljährlich fällig werden. Die PSUs werden basierend auf Leistungskennzahlen, die vom Vergütungsausschuss des Vorstands festgelegt werden, fällig, die bis zum Ende des Geschäftsjahres 2027 zwischen 50% und 140% des Ziels erreicht werden können. Beide sind an eine fortdauernde Beschäftigung gebunden.
Diese Auszeichnungen wurden im Rahmen des geänderten und neu gefassten Anreiz-Aktienoptionsplans von Twist gewährt, der der Nasdaq-Listing-Regel 5635(c)(4) für neueinstellungen oder Rückkehrer nach Beschäftigungspausen entspricht.
- Implementation of performance-based equity incentives to align employee interests with company goals
- Structured vesting schedule promotes long-term employee retention
- Potential shareholder dilution from new equity awards
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Twist, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Twist, pursuant to Nasdaq Listing Rule 5635(c)(4).
The 72,394 RSUs vest over a 48-month period for each employee as follows:
The up to 50,630 PSUs vest on achievement of certain performance metrics set by the Compensation Committee of the Company’s Board of Directors, to be achieved by no later than the end of the 2027 fiscal year (which can be earned at
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219387100/en/
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Source: Twist Bioscience Corporation
FAQ
How many equity awards did Twist Bioscience (TWST) grant in their latest inducement program?
What is the vesting schedule for TWST's new RSU grants?
What is the performance range for TWST's new PSU grants?
How many new employees received TWST's inducement equity grants?
When do TWST's new PSU grants need to achieve their performance metrics by?
